Literature DB >> 6588246

Muscle intracellular electrolytes in patients with chronic uremia.

J Bergström, A Alvestrand, P Fürst, E Hultman, U Widstam-Attorps.   

Abstract

We performed 182 percutaneous muscle biopsies in 161 nondialyzed or dialyzed patients with chronic renal failure. Muscle sodium (NaM), potassium (KM), magnesium (MgM) and phosphorus (PM) were determined by neutron activation analysis and atomic absorption spectrophotometry. Intracellular water (H2OI) in muscle was increased in all groups of uremic patients but was not correlated with total muscle water (H2OM) which varied with the content of extracellular water (H2OE). In the nondialyzed patients KM, MgM, and PM were normal in relation to fat free solids (FFS). KM/MgM and KM/PM were also normal. Alkali soluble muscle protein (ASP) was low, and KM/ASP was significantly increased. In hemodialyzed patients and in predialysis peritoneal dialysis patients, KM/FFS and KM/MgM were high. For 22 to 24 hours after peritoneal dialysis, H2OM, H2OE, ClM, NaM, KM, and PM fell significantly, but H2OI was unchanged. The calculated intracellular potassium concentration (KI/H2OI) was significantly reduced in all groups of patients, even though KM was normal or increased. This decrease became more marked when calculating H2OE, H2OI, and KI/H2OI with the chloride method, assuming a reduced muscle transmembrane potential. There was a covariation between KM and PM, KM and H2OI, and KM and plasma potassium, but not between MgM and plasma magnesium or PM and plasma inorganic phosphate. Thus, typical features of chronically uremic muscle are an increase in intracellular water and normal or increased content of potassium in relation to various reference bases representing cell mass. However, the concentration of potassium in intracellular fluid is reduced, presumably because of inhibition of the sodium pump, which reduces transmembrane potential and interferes with the volume regulation of the muscle cells.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6588246

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  7 in total

1.  Energy expenditure and outcome in patients with multiple organ failure following abdominal surgery.

Authors:  E Forsberg; M Soop; A Thörne
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

2.  Protein-sparing effect in skeletal muscle of growth hormone treatment in critically ill patients.

Authors:  L Gamrin; P Essén; E Hultman; M A McNurlan; P J Garlick; J Wernerman
Journal:  Ann Surg       Date:  2000-04       Impact factor: 12.969

3.  Comparison of Icodextrin and 2.5% Glucose in Potassium Metabolism by Acute K load via Dialysate in Continuous Ambulatory Peritoneal Dialysis Patients.

Authors:  Joo-Hark Yi; Yeo-Wook Yun; Sang-Woong Han; Ho-Jung Kim
Journal:  Electrolyte Blood Press       Date:  2009-06-30

4.  Icodextrin improves the serum potassium profile with the enhancement of nutritional status in continuous ambulatory peritoneal dialysis patients.

Authors:  Joo-Hark Yi; Jae-Il Park; Hoon-Young Choi; Ho-Yung Lee; Sang-Woong Han; Ho-Jung Kim
Journal:  Electrolyte Blood Press       Date:  2009-12-31

5.  Lower serum potassium associated with increased mortality in dialysis patients: A nationwide prospective observational cohort study in Korea.

Authors:  Sunhwa Lee; Eunjeong Kang; Kyung Don Yoo; Yunhee Choi; Dong Ki Kim; Kwon Wook Joo; Seung Hee Yang; Yong-Lim Kim; Shin-Wook Kang; Chul Woo Yang; Nam Ho Kim; Yon Su Kim; Hajeong Lee
Journal:  PLoS One       Date:  2017-03-06       Impact factor: 3.240

6.  Spironolactone is effective in treating hypokalemia among peritoneal dialysis patients.

Authors:  Amit Langote; Swapnil Hiremath; Marcel Ruzicka; Brendan B McCormick
Journal:  PLoS One       Date:  2017-11-10       Impact factor: 3.240

7.  Genome Diversity and Signatures of Selection for Production and Performance Traits in Dromedary Camels.

Authors:  Hussain Bahbahani; Hassan H Musa; David Wragg; Eltahir S Shuiep; Faisal Almathen; Olivier Hanotte
Journal:  Front Genet       Date:  2019-09-19       Impact factor: 4.599

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.